Melanoma runs on both sides of her family, with one of her grandmothers and an aunt treated for the deadliest form of skin ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

The O'Hern sisters helped each other fight breast cancer. Now they're walking in the 2025 Kentucky Oaks Survivors Parade at ...